Austria city Vienna, Austria covid-19 vaccine prevention infection Austria city Vienna, Austria

Avalon GloboCare to develop intranasal and oral Covid-19 vaccine

Reading now: 679
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.US-based biotech firm Avalon GloboCare has collaborated with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine against Covid-19 for intranasal or oral administration.

The partners are working to develop a vaccine candidate that would trigger an immune response sufficient to prevent a severe form of Covid-19 infection, which is responsible for morbidity and can lead to death.

Avalon GloboCare noted that the vaccine candidate is a fusion of an S-layer viral particle mimic and the SARS-CoV-2 spike protein.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA